Paintsville Hospital Company, LLC v. Amneal Pharmaceuticals, LLC

CourtDistrict Court, E.D. Kentucky
DecidedDecember 1, 2020
Docket7:20-cv-00102
StatusUnknown

This text of Paintsville Hospital Company, LLC v. Amneal Pharmaceuticals, LLC (Paintsville Hospital Company, LLC v. Amneal Pharmaceuticals, LLC) is published on Counsel Stack Legal Research, covering District Court, E.D. Kentucky primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Paintsville Hospital Company, LLC v. Amneal Pharmaceuticals, LLC, (E.D. Ky. 2020).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF KENTUCKY SOUTHERN DIVISION PIKEVILLE

PAINTSVILLE HOSPITAL COMPANY, ) LLC, et al. ) ) Civil. No. 7:20-cv-00102-GFVT Plaintiffs, ) ) V. ) MEMORANDUM OPINION ) & AMNEAL PHARMACEUTICALS, LLC, ) ORDER et al., ) Defendants.

*** *** *** ***

This matter is before the Court on two pending motions: Plaintiffs’ Motion to Remand [R. 8] and Defendant Wal-Mart Inc.’s (“Wal Mart”) Motion to Stay further proceedings pending a ruling by the Judicial Panel on Multidistrict Litigation (JPML) concerning the transfer of these actions to a consolidated Multidistrict Litigation (MDL) case, In re: National Prescription Opiate Litigation, MDL No. 2804. [R. 10.] For the reasons explained below, Defendant Wal- Mart Inc.’s Motion to Stay will be GRANTED. I This case is related to hundreds of other lawsuits that have been filed throughout the country in recent years. In these lawsuits, plaintiffs typically allege that certain defendants misrepresented the safety and the addictive properties of prescription opioids, failed to comply with relevant legal standards and requirements, and engaged in deceptive conduct that resulted in prescription opioids being over-distributed and over-prescribed. On December 5, 2017, the JPML determined that a large number of cases related to these allegations should be centralized for pretrial proceedings and formed MDL 2804 in the Northern District of Ohio to coordinate the resolution of these actions. See In re Nat'l Prescription Opiate Litig., 290 F. Supp. 3d 1375, 1378 (JPML 2017). Since that time, well over 2,000 cases have been transferred to the MDL Court. See In re Nat'l Prescription Opiate Litig., No. 1:17-MD-2804, 2019 WL 4686815, at *1

(N.D. Ohio Sept. 26, 2019). This case was originally filed by Plaintiffs in Johnson Circuit Court on June 8, 2020. [R. 1-2 at 11.] Defendant Wal-Mart Inc. subsequently removed to federal court, asserting that “Plaintiffs’ claims arise under federal law and effectively allege that Walmart and certain other Defendants violated and are liable under. . . the Controlled Substances Act, 21 U.S.C. §§ 801, et seq., (the “CSA”) and its implementing regulations.” [R. 1 at 3.] The JPML then issued a Conditional Transfer Order identifying the present case as “involv[ing] questions of fact that are common to the actions previously transferred to” the MDL Court. [R. 1-5.] Following removal and pending the final determination by the JPML of whether this case should be consolidated, multiple motions have been filed which now require the Court’s attention.

On July 30, 2020, Plaintiffs filed a Motion to Remand back to state court. [R. 8.] Defendant Wal-Mart Inc. filed a response in opposition to Plaintiffs’ Motion to Remand and has now also moved to stay further proceedings pending the imminent determination by the JPML. [R. 12; R. 10.] These motions have now been fully briefed, the Court has considered the arguments of the parties and applicable law, and this Opinion is the result. II The Court will address Plaintiffs’ Motion to Remand and Defendant Wal-Mart Inc.’s competing Motion to Stay pending potential transfer to the MDL simultaneously. [R. 8; R. 10.] Wal-Mart wishes to stay all proceedings, including the remand motion, until the JPML finally resolves the transfer issue. [R. 10 at 1.] On the other hand, Plaintiffs argue this Court should remand before the JPML concludes that process. [R. 8-1 at 2; R. 12 at 4.] The decision whether to grant a stay is discretionary because “the power to stay proceedings is incidental to the power inherent in every court to control the disposition of the

causes on its docket with economy of time and effort for itself, for counsel, and for litigants.” Landis v. N. Am. Co., 299 U.S. 248, 254 (1936) (Cardozo, J.); Meyers v. Bayer AG, 143 F. Supp. 2d 1044, 1047 (E.D. Wis. 2001) (quoting Landis, 299 U.S. at 254, as support for the district court’s power to stay a case pending transfer by the JPML). As relevant in the present context, the Manual for Complex Litigation notes that a “stay pending the Panel's decision can increase efficiency and consistency, particularly when the transferor court believes that a transfer order is likely and when the pending motions raise issues likely to be raised in other cases as well.” Manual for Complex Litigation (4th ed.) § 22.35 (2005). Further, 28 U.S.C. § 1407 specifically authorizes the JPML to transfer cases even when there is a motion to remand pending in the district court, although the JPML’s consideration of transfer does not

deprive the district court of its own inherent authority to rule on the remand motion itself. See Judicial Panel on Multidistrict Litigation, Rule 2.1(d). Therefore, this Court has the power to resolve the instant motions despite the ongoing JPML process. In making this determination, the Court notes that some courts choose to rule on pending motions to remand before the JPML decides to transfer the case, while many other courts decide to issue a stay pending the JPML’s decision even when a motion to remand is also pending. Compare, e.g., Kantner v. Merck & Co., 2005 WL 277688 (S.D. Ind. Jan. 26, 2005) (ruling on remand motion before any potential transfer by JPML); with Benge v. Eli Lilly & Co., 553 F. Supp. 2d 1049 (N.D. Ind. 2008) (staying all proceedings pending final resolution by JPML concerning transfer); Aetna U.S. Healthcare, Inc. v. Hoechst Aktiengesellschaft, 48 F. Supp. 2d 37, 43 (D.D.C. 1999) (same); Rivers v. The Walt Disney Co., 980 F. Supp. 1358 (C.D. Cal. 1997) (same). Indeed, as briefed at length by the parties, in many cases related to the litigation at hand courts have also issued stays while others have chosen to remand the case before the

question of transfer is fully resolved. [See R. 10 at 2, n. 2 (citing multiple cases in Kentucky which were ultimately transferred to a JPML); R. 8-1 at 3, n. 3 (citing and discussing several cases related to the instant litigation where district courts remanded actions during the pendency of conditional transfer orders).] Invariably, however, courts consider the interests of judicial economy and potential prejudice or hardship to the parties—an inquiry which is necessarily specific to the individual facts and procedural posture of each case, and which is likely the main cause for the apparent divergence of approaches. In considering the present cases, the Court finds persuasive the extensive and thoughtful explanation behind the approach adopted in Meyers v. Bayer AG. 143 F. Supp. 2d at 1049. In that case, the court employed an approach by which the district court makes a preliminary

assessment of jurisdiction, and if, upon such assessment, jurisdiction is clearly improper, “the court should promptly complete its consideration and remand the case to state court.” Id. If jurisdiction is not clearly improper, the district court is then to turn to additional considerations in making its stay determination. Id. Although not binding, this reasoned approach also seems consistent with guidance concerning the MDL process in general, which provides that a primary reason for denying a stay pending the panel’s decision on transfer is when federal jurisdiction is clearly absent. Manual for Complex Litigation (4th ed.) § 22.35.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kucana v. Holder
558 U.S. 233 (Supreme Court, 2010)
Landis v. North American Co.
299 U.S. 248 (Supreme Court, 1936)
Benge v. Eli Lilly and Co.
553 F. Supp. 2d 1049 (N.D. Indiana, 2008)
In Re Penn Central Securities Litigation
333 F. Supp. 382 (Judicial Panel on Multidistrict Litigation, 1971)
Rivers v. Walt Disney Co.
980 F. Supp. 1358 (C.D. California, 1997)
In Re Prudential Ins. Co. of America Sales Pract.
170 F. Supp. 2d 1346 (Judicial Panel on Multidistrict Litigation, 2001)
Aetna U.S. Healthcare, Inc. v. Hoechst Aktiengesellschaft
48 F. Supp. 2d 37 (District of Columbia, 1999)
Meyers v. Bayer AG
143 F. Supp. 2d 1044 (E.D. Wisconsin, 2001)
In Re Bayer Corp. Combination Aspirin Products Marketing & Sales Practices Litigation
609 F. Supp. 2d 1379 (Judicial Panel on Multidistrict Litigation, 2009)
In re Nat'l Prescription Opiate Litig.
290 F. Supp. 3d 1375 (Judicial Panel on Multidistrict Litigation, 2017)
Dunaway v. Purdue Pharma L.P.
391 F. Supp. 3d 802 (M.D. Tennessee, 2019)
Curtis v. BP America, Inc.
808 F. Supp. 2d 976 (S.D. Texas, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Paintsville Hospital Company, LLC v. Amneal Pharmaceuticals, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/paintsville-hospital-company-llc-v-amneal-pharmaceuticals-llc-kyed-2020.